On Tuesday, Syros Pharmaceuticals Inc (NASDAQ: SYRS) was -0.04% drop from the session before settling in for the closing price of $0.24. A 52-week range for SYRS has been $0.18 – $8.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 128.79%. When this article was written, the company’s average yearly earnings per share was at 73.32%. With a float of $17.43 million, this company’s outstanding shares have now reached $26.83 million.
Let’s determine the extent of company efficiency that accounts for 68 employees. In terms of profitability, gross margin is -228.76%, operating margin of -28892.23%, and the pretax margin is -25340.67%.
Syros Pharmaceuticals Inc (SYRS) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Syros Pharmaceuticals Inc stocks. The insider ownership of Syros Pharmaceuticals Inc is 35.06%, while institutional ownership is 36.36%. The most recent insider transaction that took place on Dec 10 ’24, was worth 1,533. Before that another transaction happened on Dec 02 ’24, when Company’s Director sold 37,070 for $0.27, making the entire transaction worth $10,016. This insider now owns 4,000 shares in total.
Syros Pharmaceuticals Inc (SYRS) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.7 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 73.32% per share during the next fiscal year.
Syros Pharmaceuticals Inc (NASDAQ: SYRS) Trading Performance Indicators
You can see what Syros Pharmaceuticals Inc (SYRS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.25. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.03, a number that is poised to hit -0.69 in the next quarter and is forecasted to reach -2.05 in one year’s time.
Technical Analysis of Syros Pharmaceuticals Inc (SYRS)
Looking closely at Syros Pharmaceuticals Inc (NASDAQ: SYRS), its last 5-days average volume was 2.04 million, which is a drop from its year-to-date volume of 2.37 million. As of the previous 9 days, the stock’s Stochastic %D was 31.01%. Additionally, its Average True Range was 0.15.
During the past 100 days, Syros Pharmaceuticals Inc’s (SYRS) raw stochastic average was set at 0.90%, which indicates a significant decrease from 27.75% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 100.06% in the past 14 days, which was lower than the 375.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4754, while its 200-day Moving Average is $3.9321. However, in the short run, Syros Pharmaceuticals Inc’s stock first resistance to watch stands at $0.2511. Second resistance stands at $0.2583. The third major resistance level sits at $0.2669. If the price goes on to break the first support level at $0.2353, it is likely to go to the next support level at $0.2267. Should the price break the second support level, the third support level stands at $0.2195.
Syros Pharmaceuticals Inc (NASDAQ: SYRS) Key Stats
There are 26,832K outstanding shares of the company, which has a market capitalization of 6.54 million. As of now, sales total 9,940 K while income totals -164,570 K. Its latest quarter income was 0 K while its last quarter net income were -6,400 K.
